Brief: ArgenX: Phase 2 Data Establish Proof-Of-Concept Of Efgartigimod

argenx SE

20/11/2024 06:20

Nov 20 (Reuters) - argenx SE  ARGX.BR :
    * ARGENX ADVANCES CLINICAL DEVELOPMENT OF EFGARTIGIMOD SC IN
IDIOPATHIC INFLAMMATORY MYOPATHIES
    * PHASE 2 DATA ESTABLISH PROOF-OF-CONCEPT OF EFGARTIGIMOD SC
IN
MYOSITIS
    * ENROLLMENT TO CONTINUE IN PHASE 3 ACROSS ALL THREE
SUBTYPES
    * ALKIVIA STUDY TO ENROLL 240 PATIENTS IN TWO PHASES

Source text:  ID:nGNE5wZbnf 
Further company coverage:  ARGX.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))